Respiratory Medicine and Research最新文献

{"title":"Prognostic value of the mini nutritional assessment short-form and SpO₂/FiO₂ ratio at admission for in-hospital mortality in patients with interstitial lung disease","authors":"Mayuko Ishiwari,&nbsp;Yuta Kono,&nbsp;Yuki Togashi,&nbsp;Kenichi Kobayashi,&nbsp;Ryota Kikuchi,&nbsp;Mariko Kogami,&nbsp;Shinji Abe","doi":"10.1016/j.resmer.2025.101222","DOIUrl":"10.1016/j.resmer.2025.101222","url":null,"abstract":"<div><h3>Background</h3><div>Hospitalization of patients with interstitial lung disease (ILD) is a poor prognostic factor. Simple and rapid biomarkers at the time of admission of hospitalized ILD patients are needed. The aim of this study was to investigate prognostic biomarkers in hospitalized patients with ILD.</div></div><div><h3>Methods</h3><div>A total of 95 consecutive hospitalized patients aged ≥ 65 years with ILD were retrospectively enrolled from April 2022 to December 2024 at Tokyo Medical University Hospital, Tokyo, Japan. Clinical and laboratory parameters at admission were retrospectively collected, and risk factors for in-hospital mortality were evaluated.</div></div><div><h3>Results</h3><div>The median age was 77 years (IQR: 72–83), and 62 patients (65.0 %) were male. Sixty-nine patients (73.0 %) were ex-smokers. Thirty patients (31.5 %) died during hospitalization, with a median time to death of 19 days (IQR: 10–28). Univariable analysis revealed that a low SpO₂/FiO₂ (S/F) ratio (&lt;419) (<em>p</em> = 0.0003), high neutrophil-to-lymphocyte ratio (NLR) (≥6.5) (<em>p</em> = 0.0003), Glasgow Prognostic Score (GPS) 2 (<em>p</em> = 0.0383), and low Mini Nutritional Assessment Short-Form (MNA-SF) score (&lt;11) (<em>p</em> = 0.0007) were significantly associated with in-hospital mortality of hospitalized patients with ILD. In the multivariable analysis, S/F ratio (<em>p</em> = 0.0116) and low MNA-SF score (<em>p</em> = 0.0289) had a significant effect on the prognosis of hospitalized patients with ILD.</div></div><div><h3>Conclusions</h3><div>Nutritional risk assessed by the MNA-SF, together with oxygenation status measured by the S/F ratio, could serve as valuable and readily available prognostic biomarkers for hospitalized patients with ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101222"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MUC5B polymorphism and post COVID-19 lung abnormalities on chest CT-scan","authors":"Celestie Yaacoub ,&nbsp;Coralie Tardivon ,&nbsp;Jean Dib ,&nbsp;Spyridon Prountzos ,&nbsp;Joe Yazbeck ,&nbsp;Elvira-Markela Antonogiannaki ,&nbsp;Ibrahima Ba ,&nbsp;Christina Kontopoulou ,&nbsp;Pinelopi Kazakou ,&nbsp;Lykourgos Kolilekas ,&nbsp;Anastasia Antoniadou ,&nbsp;Bruno Crestani ,&nbsp;Spyros A. Papiris ,&nbsp;Effrosyni D. Manali ,&nbsp;Quentin Philippot ,&nbsp;Antoine Khalil ,&nbsp;Cedric Laouenan ,&nbsp;Raphael Borie ,&nbsp;Marie-Pierre Debray ,&nbsp;on behalf of the French COVID cohort study group","doi":"10.1016/j.resmer.2025.101207","DOIUrl":"10.1016/j.resmer.2025.101207","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101207"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns, healthcare resource utilization, and healthcare costs in patients in the United States with metastatic non-small cell cancer receiving second or subsequent line systemic anticancer therapy","authors":"Divyan Chopra ,&nbsp;Ihtisham Sultan ,&nbsp;David M. Waterhouse ,&nbsp;Alexander Lonshteyn ,&nbsp;Thomas E. Delea ,&nbsp;Björn Stollenwerk","doi":"10.1016/j.resmer.2025.101197","DOIUrl":"10.1016/j.resmer.2025.101197","url":null,"abstract":"<div><h3>Background</h3><div>This study assessed real-world treatment patterns, healthcare resource utilization, and healthcare costs in the US adults with metastatic non-small cell lung cancer (NSCLC) receiving second or later line (2L+) treatment for non-actionable alterations.</div></div><div><h3>Methods</h3><div>Adults with metastatic NSCLC who received 2L+ treatment for non-actionable alterations from January 1, 2020, to March 31, 2023, were identified using the US Optum deidentified Clinformatics® database. Patients were continuously enrolled in health plans for ≥180 days before NSCLC diagnosis until ≥30 days after receiving treatment.</div></div><div><h3>Results</h3><div>5310 patients met the inclusion criteria and received 2L+ treatments (7010). Median age was 73 years; 86% were insured by Medicare Advantage. Commonly used 2L+ treatments were mono or dual immunotherapy (IO) without chemotherapy (CT) (43.2%) and IO plus platinum-based CT (PBCT) (13.4%). Median treatment duration and time to next treatment were 3.8 months and 6.0 months respectively and were low for CT without IO. Healthcare resource utilization was mainly attributed to outpatient visits (mean: 5.09 per-patient per-month [PPPM]) and were highest for CT without IO. Patients receiving CT without IOs also had the highest rates of inpatient and emergency utilization. Mean total healthcare costs were $27,105 PPPM with hospitalization costs being highest for CT without IO.</div></div><div><h3>Conclusions</h3><div>In the treatment of 2L+ metastatic NSCLC, chemotherapy without IO was associated with poor treatment duration, high inpatient, emergency care utilization, and substantial economic burden. These results highlight the need for more efficacious, safe and cost-efficient treatment options in the 2L+ setting.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101197"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of exhaled breath and serum markers following a single bout of exercise in COPD patients - a case-control study.","authors":"Rembert Koczulla, Tobias Boeselt, Albrecht Sitte Zoellner, Rainer Gloeckl, Daniela Kroll, Inga Jarosch, Tessa Schneeberger, Julia Held, Sabina Janciauskiene","doi":"10.1016/j.resmer.2025.101193","DOIUrl":"10.1016/j.resmer.2025.101193","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"101193"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice","authors":"Christos Chouaid ,&nbsp;Philippe Giraud ,&nbsp;Marie Wislez ,&nbsp;Eric Pichon ,&nbsp;Alma Stancu ,&nbsp;Didier Debieuvre ,&nbsp;Nicolas Girard ,&nbsp;Maurice Pérol ,&nbsp;Xavier Quantin ,&nbsp;Sabine Ano ,&nbsp;Françoise Grela ,&nbsp;Nina Goyard ,&nbsp;Mathieu Fore ,&nbsp;Fanny Magne ,&nbsp;Vanessa Pante ,&nbsp;Lydie Lemonnier-Videau ,&nbsp;Lionel Falchero","doi":"10.1016/j.resmer.2025.101216","DOIUrl":"10.1016/j.resmer.2025.101216","url":null,"abstract":"<div><h3>Background</h3><div>Durvalumab consolidation therapy has improved survival after chemoradiotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Our three-cohort study from France described the real-world effectiveness and safety of durvalumab in unresectable stage III NSCLC.</div></div><div><h3>Methods</h3><div>We analysed three durvalumab-treated cohorts: the French PACIFIC-R cohort (n=342), the prospective KBP-2020-CPHG cohort (n=178), and the ESME lung cancer registry (n=604). Progression-free survival (PFS) and overall survival (OS) were assessed from start of durvalumab (in French PACIFIC-R and KBP-2020-CPHG) or end of radiotherapy (in ESME). Safety data were available for the French PACIFIC-R cohort.</div></div><div><h3>Results</h3><div>In French PACIFIC-R, at a median follow-up of 39.4 months, median PFS was 22.6 months and median OS was not reached. At 3 years, OS was 61.1%. Median PFS was 13.0 months in patients with programmed death-ligand 1 (PD-L1) expression &lt;1% versus 25.3 months in those with PD-L1 ≥1%. Pneumonitis/interstitial lung disease occurred in 17.8% of patients, with no fatal events. In KBP-2020-CPHG, median PFS was 18.5 months and median OS was not reached. Three-year OS was 55.0%. Patients with PD-L1 expression &gt;50% had a 3-year OS rate of 68.4% compared to 48.5% in those with PD-L1 expression 1%–50%. In ESME, median PFS was 21.2 months and median OS was 50.7 months. The 3-year and 5-year OS rates were 61.3% and 46.9%, respectively. Among 308 patients with N2 stage disease, median PFS was 25.6 months and median OS was 56.4 months from NSCLC diagnosis.</div></div><div><h3>Conclusions</h3><div>Real-world evidence from three large French cohorts underscores the sustained effectiveness and manageable safety profile of durvalumab consolidation therapy after chemoradiotherapy in unresectable stage III NSCLC.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101216"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Six-minute walking distance is a robust predictor of mortality in stable chronic obstructive pulmonary disease without major comorbidities","authors":"Brede Kvisvik ,&nbsp;Ingunn Skjørten ,&nbsp;Janne Mykland ,&nbsp;Torbjørn Omland ,&nbsp;Morten Nissen Melsom ,&nbsp;Sjur Humerfelt ,&nbsp;Kjetil Steine","doi":"10.1016/j.resmer.2025.101214","DOIUrl":"10.1016/j.resmer.2025.101214","url":null,"abstract":"<div><h3>Background</h3><div>Most patients with COPD are examined with specific pulmonary function tests and blood samples in addition to six-minute walking distance (6MWD), while few are examined by echocardiography and even fewer by invasive right heart catheterization (RHC). However, the relative prognostic value of these indices of disease remains to be defined.</div></div><div><h3>Aim</h3><div>We aimed in the present study to identify predictors of mortality in a cohort of COPD patients who had undergone comprehensive testing of pulmonary function, echocardiography and RHC.</div></div><div><h3>Material and methods</h3><div>The study included 97 outpatients with stable COPD in GOLD stages I-IV, after excluding three patients receiving a lung transplant. All patients underwent preinclusion screening where patients with left ventricular disease and other major comorbidities were excluded. Spirometry, blood tests, 6MWD and echocardiography of right and left heart were carried out, and RHC was performed at rest.</div></div><div><h3>Results</h3><div>During a mean follow-up of 7.6 ± 0.6 years, 44 patients died. Pulmonary hypertension was diagnosed in 32 patients (33 %) and was associated with mortality (<em>p</em> = 0.029). 6MWD, right ventricular tricuspid annular plane systolic excursion and myocardial performance index, mean pulmonary artery pressure, pulmonary vascular resistance, arterial oxygen tension, forced expiratory volume in one second, and oxygen uptake were all associated with mortality. However, 6MWD was the only significant variable in the multivariable Cox regression model (<em>p</em> = 0.001).</div></div><div><h3>Conclusions</h3><div>6MWD was the most robust prognostic determinant of mortality in a stable COPD population free of major comorbidities.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101214"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of complementary medicines and self-medication practices in cystic fibrosis – MUCAUTOMED study","authors":"Sophie Lemagner ,&nbsp;Isabelle Récoché ,&nbsp;Frédéric Eyvrard ,&nbsp;Remy Chambault ,&nbsp;Marie Mittaine ,&nbsp;Marlène Murris","doi":"10.1016/j.resmer.2025.101186","DOIUrl":"10.1016/j.resmer.2025.101186","url":null,"abstract":"<div><h3>Background</h3><div>Cystic fibrosis (CF) patients often undergo treatment with CFTR modulators, which have demonstrated high efficacy but also potential involvement in drug interactions. Inquiries regarding the risks of drug interactions with complementary and alternative medicine products (CAMp) and self-medication drugs have become frequent among patients and prescribers at Toulouse University Hospital. Currently, there is lack of literature on these practices within CF patients, particularly in France, and more so since the advent of CFTR modulators.</div></div><div><h3>Methods</h3><div>This observational monocentric study (MUCAUTOMED) aimed to characterize and quantify the prevalence of CAMp utilization among CF patients under our hospital's care. A secondary objective was to assess and describe the prevalence of self-medication practices. Surveys were administered to outpatients during visits from January 10 to June 6, 2022.</div></div><div><h3>Results</h3><div>Out of 171 included patients, responses from 64 adults and 69 children were analyzed (response rate 133/171 = 77.8 %). CAMp usage was reported by 56.3 % of adults and 46.4 % of children. Most patients use CAMp for enhancing wellness, addressing digestive concerns, and managing respiratory issues. Remarkably, 71.4 % of participants were unaware of potential drug interactions with CAMp, and 48.9 % initiated such use without consulting healthcare professionals. Notably, a significant correlation between CAMp utilization and self-medication was identified within the pediatric population.</div></div><div><h3>Conclusion</h3><div>Our investigation underscores a notably high prevalence of CAMp use among the CF population. Given these findings, it is imperative to routinely discuss CAMp utilization and self-medication practices when initiating CFTR modulator therapy. A multidisciplinary approach is recommended to address potential interactions that may impact overdosing and underdosing, ensuring patients and families are informed of associated risks.</div><div>Registration number 2021-A02593-38.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101186"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144771906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early mobilization and functional outcomes in cystic fibrosis patients after lung transplantation: A single-center retrospective study","authors":"Matthieu Reffienna ,&nbsp;Jeremy Roussel ,&nbsp;Gabor Kalman ,&nbsp;Mathilde Labro ,&nbsp;Charles Cerf ,&nbsp;François Parquin","doi":"10.1016/j.resmer.2025.101184","DOIUrl":"10.1016/j.resmer.2025.101184","url":null,"abstract":"<div><h3>Background</h3><div>Rehabilitation has been shown to enhance patient performance before and after lung transplantation, but limited data exist on its role during the immediate post-transplant phase in critical care units.</div></div><div><h3>Methods</h3><div>We conducted a single-center retrospective study. All adult patients who underwent bilateral transplantation for cystic fibrosis were included. Patients were followed from admission to discharge from critical care. All rehabilitation sessions were recorded. We aimed to evaluate the relationship between the amount of mobilization performed by the patient in critical care, and functional performance at discharge.</div></div><div><h3>Results</h3><div>We included 36 patients (21 males) with a median age of 29 years (IQR: 24.5–35.0) and a median critical care length of stay of 15 days (12.5–20). Patients performed a total of 388 sessions of rehabilitation. Out-of-bed mobilization started at a median of post-operative day 2.5 (IQR: 1.0–4.5), with the first walking session at day 3 (IQR: 2.0–4.5). A strong correlation was found between daily walking distance and functional performance, as measured by the 6-minute walk test, with a Pearson correlation coefficient of 0.70 (95 % CI: 0.48–0.84).</div></div><div><h3>Conclusions</h3><div>After lung transplantation for cystic fibrosis, early initiated rehabilitation in critical care is feasible and can improve patients' functional performance. These findings are promising, but require validation in other lung transplant populations.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101184"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endobronchial valve (EBV) insertion for severe emphysema does not improve skeletal muscle mass or function: A pilot study on 19 patients","authors":"Julia Rubenstein ,&nbsp;Ilyès Benlala ,&nbsp;Emilie Mesa ,&nbsp;Anne-Claire Toublanc ,&nbsp;Marina Gueçamburu ,&nbsp;Arnaud Maurac ,&nbsp;Claire Bon ,&nbsp;Charlotte Vergnenegre ,&nbsp;Léo Grassion ,&nbsp;Geoffroy Moucheboeuf ,&nbsp;Patrick Dehail ,&nbsp;Gaël Dournes ,&nbsp;Maéva Zysman ,&nbsp;Pauline Henrot","doi":"10.1016/j.resmer.2025.101178","DOIUrl":"10.1016/j.resmer.2025.101178","url":null,"abstract":"<div><div>Endobronchial valve (EBV) insertion for severe emphysema allows to reduce hyperinflation and alleviates respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD). However, few studies investigate its effect on extra-pulmonary manifestations. We sought to assess the effect of EBV insertion on skeletal muscle mass and function, as well as determine if skeletal muscle parameters could represent a prognostic factor for response to EBV insertion.</div><div>We conducted a monocentric prospective pilot study including 19 patients. Exhaustive evaluation of lung &amp; skeletal muscle parameters was performed at baseline and 3 and 6 months after EBV insertion. Our primary aim was to assess the 6-month change in skeletal muscle parameters i.e. assessment of body composition with bioimpedance analysis (appendicular skeletal muscle mass index, fat mass, phase angle), evaluation of thoracic muscles (pectoralis, erector spinal, 5th intercostalis, psoas) surfaces and densities on CT-scans, and of upper limb force with handgrip test.</div><div>EBV insertion led to a significant improvement of lung function after 3 months and persisting at 6 months. In contrast, no significant improvement was observed in skeletal muscle parameters. In addition, no muscle parameter nor sarcopenic status was found to predict response to EBV insertion.</div><div>These results suggest that EBV insertion is not associated with strong systemic effects in our study, as well as emphasize the need to find bottom-up drug strategies for COPD-associated sarcopenia.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101178"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological disparities in pulmonary sarcoidosis between public and private healthcare sectors in haute-Garonne department (France).","authors":"Nicolas Le Divenah, Grégoire Prévot, Aurélie Le Borgne, Florence Lintz, Gisèle Mourin, Pierre-Jean Esquerre, Jean-Christophe Aubry, William Heurtaux, Laura Petrov, Emilie Bousquet, Myriam Delaunay, Guillaume Faviez, Meritxell Pasto-Catusse, Jean-Marc Vernejoux, Marie-Christine Pujazon, Romain Barthes, Alain Didier, Julien Mazières, Nicolas Guibert, Thomas Villeneuve","doi":"10.1016/j.resmer.2025.101177","DOIUrl":"10.1016/j.resmer.2025.101177","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcoidosis is a multisystem granulomatous disorder that affects mediastinal and pulmonary structures in nearly 90% of cases. Given the high prevalence of respiratory involvement, pulmonologists are crucial in managing the disease, from diagnosis through to follow-up. In France, epidemiological data on sarcoidosis are limited, despite notable regional and international variations in the incidence and prevalence of the disease.</p><p><strong>Materials and methods: </strong>The SARCOPIDEMIO study is a prospective, multicenter observational study designed to estimate the incidence and prevalence of pulmonary sarcoidosis in the Haute-Garonne department (France). A total of 55 pulmonologists, representing both hospital-based and private practices, were invited to participate.</p><p><strong>Results: </strong>A total of 172 patients were included in the analysis. The minimal and estimated prevalence rates were determined to be 14.8 to 29.6 cases per 100,000 inhabitants, respectively. The incidence rate was 3.6 new cases per 100,000 inhabitants per year. Histological confirmation of granuloma was obtained in approximately 78% of the patients. Half of the patients received corticosteroid therapy, while one-quarter were treated with second-line immunosuppressive agents. The distribution of patients between public and private sectors was relatively balanced; however, multisystemic clinical presentations and the need for treatment were more frequently observed in hospital settings.</p><p><strong>Conclusion: </strong>The epidemiological data on pulmonary sarcoidosis from the Haute-Garonne department are relatively with those previously reported in France. Although sarcoidosis is a rare disease, its management is shared by all pulmonologists in our region.</p>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"101177"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}